These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28944731)

  • 1. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
    Gupta R; Dhruva SS; Fox ER; Ross JS
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1066-1076. PubMed ID: 28944731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
    Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
    Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
    J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the Impact of Food and Drug Administration's Unapproved Drug Initiative on Drug Prices and Sales.
    Sharma D; Schumock GT; Saffore CD; Albert Edwards S; Walton SM
    Ther Innov Regul Sci; 2020 Mar; 54(2):424-430. PubMed ID: 32072591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
    Ostroff C; Lee CE; McMeekin J
    Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.
    J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
    Horrow C; Gabriele SME; Tu SS; Sarpatwari A; Kesselheim AS
    JAMA Intern Med; 2024 Jul; 184(7):810-817. PubMed ID: 38739386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
    Eur J Health Econ; 2024 Aug; 25(6):979-997. PubMed ID: 37962724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.
    Jenei K; Gentilini A; Haslam A; Prasad V
    Lancet Oncol; 2024 Aug; 25(8):979-988. PubMed ID: 39004098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of purchases of unapproved medications by the Veterans Health Administration.
    Carico RL; Emmendorfer TR; Aspinall SL; Mizah MT; Good CB
    Am J Health Syst Pharm; 2019 Nov; 76(23):1934-1943. PubMed ID: 31628792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
    Hung A; Vu Q; Mostovoy L
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.
    Chambers JD; Pope EF; Wilkinson CL; Neumann PJ
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1240-1246. PubMed ID: 30479201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unapproved drugs--the drug information pharmacists' perspective.
    Giouroukakis M; Dryer M
    J Pharm Pract; 2013 Apr; 26(2):112-9. PubMed ID: 23459285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.
    Dave CV; Pawar A; Fox ER; Brill G; Kesselheim AS
    Value Health; 2018 Nov; 21(11):1286-1290. PubMed ID: 30442275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.